Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer
- 1 February 2007
- journal article
- editorial
- Published by Wiley in European Journal of Immunology
- Vol. 37 (2) , 310-314
- https://doi.org/10.1002/eji.200636978
Abstract
A persistent human papillomavirus (HPV) infection is considered causal and necessary for the continued growth of cervical cancer. Thus, vaccination against HPV represents a plausible approach to prevent and treat cervical cancer. A report in the current issue of the European Journal of Immunology describes a therapeutic HPV DNA vaccination strategy using the HPV‐16 E7 antigen fused to the invariant chain to enhance the E7‐specific CD8+ and CD4+ T cell immune responses, resulting in a potent anti‐tumor effect against E7‐expressing tumors. Continued exploration of HPV therapeutic DNA vaccines may lead to eventual clinical application.See accompanying article http://dx.doi.org/10.1002/eji.200636233Keywords
This publication has 22 references indexed in Scilit:
- DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protectionEuropean Journal of Immunology, 2007
- How will HPV vaccines affect cervical cancer?Nature Reviews Cancer, 2006
- COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and HowAnnual Review of Immunology, 2006
- CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVOAnnual Review of Immunology, 2005
- ZYC101a for Treatment of High-Grade Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2004
- Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targetingMethods, 2003
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- DNA Vaccines: Immunology, Application, and OptimizationAnnual Review of Immunology, 2000
- Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigensVaccine, 1998
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989